<DOC>
	<DOCNO>NCT00679172</DOCNO>
	<brief_summary>This study investigate safety , tolerability immunogenicity typhoid fever vaccine candidate M01ZH09 manufacture commercial scale , new manufacturing facility . The vaccine deliver single oral dose healthy , typhoid vaccine-na√Øve adult .</brief_summary>
	<brief_title>Immunogenicity , Safety Tolerability Typhoid Fever Vaccine Candidate M01ZH09 Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Typhoid Fever</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>healthy adult subject age 18 50 year inclusive , able willing give inform consent , follow detailed explanation participation protocol available duration study available schedule potential additional visit woman pregnant , breastfeed childbearing potential unwilling use reliable method contraception throughout study period history anaphylactic shock follow vaccination route phenylketonuria hypersensitivity component vaccine hypersensitive two follow antibiotic : ciprofloxacin , azithromycin , ampicillin , trimethoprim sulfamethoxazole receive antibiotic medication within 14 day prior dose receive vaccine within 4 week prior dose plan receive vaccine within 4 week dose receive vaccine Salmonella typhi ( licensed investigational ) ever suffer typhoid fever subject test positive hepatitis B , hepatitis C , HIV human leucocyte antigen B27 know suspected history liver active gall bladder disease , ongoing gastrointestinal disease abnormality commercial food handler health care worker direct contact high risk patient household contact immunocompromised individual , pregnant woman child le 2 year age subject clinically significant amount protein haemoglobin urine abnormality haematology serum biochemistry parameter impairment immune function receive receive cytotoxic drug 6 month prior study entry subject use antacid , proton pump inhibitor H2 blocker regular basis consume proton pump inhibitor H2 blocker within 24 hour prior dose acute infection ( include fever 37.5 degree Celsius great ) day dose . subject chronic disease ( e.g Crohn 's disease , inflammatory bowel disease , diabetes ) withstand 3 hour fast substance abuse history substance abuse might interfere participation study body mass index ( BMI ) less 19 great 34 kg per m2 clinically significant medical condition precludes participation study subject participate interventional clinical trial within 60 day dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>